Overview

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the acute treatment of migraine headache.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline